reports
Viveve Reports Preliminary Full Year 2018 Financial Results, Announces...
Viveve Reports Preliminary Full Year 2018 Financial Results, Announces 2019 Revenue Guidance and Provides Corporate Update - Company reports $18.5 million in preliminary full year 2018 revenue, representing 21% year-over-year growth, and announces revenue guidance of $20.0 million for 2019 - Company undergoes restructuring to reduce operating expenses and focus on label expansion and market development - Board announces election of Steven Basta as Chairman ENGLEWOOD, Colo., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on...
Viveve Completes Enrollment in LIBERATE-International Trial for Improv...
Viveve Completes Enrollment in LIBERATE-International Trial for Improvement of Stress Urinary Incontinence ENGLEWOOD, Colo., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, announced today that it has completed enrollment in its LIBERATE-International trial, a multicenter, randomized, double-blinded, sham-controlled study to evaluate the safety and efficacy of its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of stress urinary incontinence (SUI) in women. T...
Viveve Announces FDA Clearance to Advance VIVEVE II Clinical Study to ...
Viveve Announces FDA Clearance to Advance VIVEVE II Clinical Study to Full Enrollment - Sites to continue enrollment up to 250 patients in sexual function trial - ENGLEWOOD, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to continue enrollment in the company’s multicenter randomized Viveve Treatment of the Vaginal Introitus to EValuate Safety and Efficacy (VIVEVE II) clinical trial to assess the saf...
Viveve Announces Closing of Public Offering of Shares of Common Stock
Viveve Announces Closing of Public Offering of Shares of Common Stock ENGLEWOOD, Colo., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (“Viveve”) (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced the closing of its previously announced underwritten public offering of 13,333,334 shares of its common stock at a public offering price of $1.50 per share. The net proceeds to Viveve from the offering were approximately $18.8 million, after deducting underwriting discounts and commissions (but before deducting estimated offering expenses pay...
Viveve Announces Pricing of Public Offering of Shares of Common Stock
Viveve Announces Pricing of Public Offering of Shares of Common Stock ENGLEWOOD, Colo., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (“Viveve”) (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a public offering price of $1.50 per share. The gross proceeds to Viveve from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Viveve, are expected to be $20.0 million. All shares of co...
Viveve Announces Positive 12-Month Data from Stress Urinary Incontinen...
Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study — 72% of women treated experienced an improvement in the one-hour pad weight with an overall mean improvement of 56% — Clinically meaningful benefit achieved at one year across all patient-reported outcome measures — Complete results to be presented during live webcast of SUI symposium with physician key opinion leaders on December 11, 2018 ENGLEWOOD, Colo., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE) (“Viveve”), a medical technology company focused on women's i...
Viveve Announces Proposed Public Offering of Shares of Common Stock
Viveve Announces Proposed Public Offering of Shares of Common Stock ENGLEWOOD, Colo., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (“Viveve”) (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock will be offered by Viveve. Viveve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock in connection with the public offering. Viveve intends to use the net proceeds from ...
Viveve to Host Stress Urinary Incontinence Symposium with Physician Op...
Viveve to Host Stress Urinary Incontinence Symposium with Physician Opinion Leaders Twelve-month data from the SUI feasibility study to be presented ENGLEWOOD, Colo., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it will host a live webcast of its Key Opinion Leader symposium focused on stress urinary incontinence (SUI) on Tuesday, December 11, 2018 beginning at 10:00am ET. The symposium will address the use of the company’s proprietary, cryogen-cooled monopolar radiofrequency ...
Viveve Named One of North America’s 500 Fastest Growing Companies by...
Viveve Named One of North America’s 500 Fastest Growing Companies by Deloitte Company awarded sixth place overall and is only medical device company listed in the top ten ENGLEWOOD, Colo., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the company has been included in Deloitte’s 2018 Technology Fast 500, a list of the 500 fastest growing technology, media, telecommunications, life sciences, and energy technology companies in North America. “We are proud to be acknowledged as the...
Viveve to Present at Stifel 2018 Healthcare Conference
Viveve to Present at Stifel 2018 Healthcare Conference ENGLEWOOD, Colo., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Stifel 2018 Healthcare Conference on Tuesday, November 13th at 8:45 AM ET in New York City. Mr. Durbin will provide an update on the company's development strategies and commercialization efforts in the United States and abroad. He will also meet with members of the investment community durin...
Viveve Reports Third Quarter 2018 Financial Results
Viveve Reports Third Quarter 2018 Financial Results Continued commercial growth for Viveve® System including record quarter of treatment tip sales Significant advancement of clinical programs targeting new indications in sexual function and stress urinary incontinence (SUI) ENGLEWOOD, Colo., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial results for the third quarter ended September 30, 2018. Total revenue for the three months ended September 30, 2018 was $4.8 million and...
Viveve to Host Conference Call to Discuss Third Quarter 2018 Financial...
Viveve to Host Conference Call to Discuss Third Quarter 2018 Financial and Operating Results ENGLEWOOD, Colo., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it will report financial results for the third quarter ended September 30, 2018 after the close of the U.S. financial markets on Thursday, November 8, 2018. Management will host a live conference call and webcast to discuss these results and provide an update on corporate and commercial developments on Friday, November 9, 201...
Viveve to Present at Ladenburg Thalmann 2018 Healthcare Conference
Viveve to Present at Ladenburg Thalmann 2018 Healthcare Conference ENGLEWOOD, Colo., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the 2018 Ladenburg Thalmann Healthcare Conference on Tuesday, October 2nd at 10:00 AM ET in New York City. Mr. Durbin will provide an update on the company's development strategies and commercialization efforts in the United States and abroad. He will also meet with members of the in...
Viveve Appoints Two New Independent Board Members
Viveve Appoints Two New Independent Board Members ENGLEWOOD, Colo., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that Steve Basta and Karen Zaderej have joined the Viveve board of directors, effective today. “It is with great pleasure that I welcome both Steve and Karen to our board, especially during this very important period of momentum and growth for the company. Steve has extensive experience building businesses to commercial success and through profitable acquisition, partic...
Viveve Submits Investigational Device Exemption to FDA to Conduct LIBE...
Viveve Submits Investigational Device Exemption to FDA to Conduct LIBERATE-U.S. Trial for Improvement of Stress Urinary Incontinence ENGLEWOOD, Colo., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for authorization to begin LIBERATE-U.S., a multicenter, randomized, double-blinded, sham-controlled trial to evaluate the safety and efficacy of the Company’s proprietary, cryogen-cooled ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.